Skip to main content

Medicine Matters oncology

Colorectal cancer

  • Patients ≥12 years old with mismatch repair-deficient and microsatellite instability high metastatic disease and with progression after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan

Classical Hodgkin lymphoma

  • Patients who have relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin

Hepatocellular carcinoma

  • Patients who have had prior treatment with sorafenib

Head and neck cancer

  • Advanced squamous NSCLC patients with progression on or after platinum-based chemotherapy

​​​​​​​Non-small-cell lung cancer

  • Advanced squamous NSCLC that has progressed on or after platinum-based chemotherapy

Small-cell lung cancer

  • Patients with metastatic disease refractory to platinum-based chemotherapy and at least one other line of treatment


  • Newly diagnosed advanced-stage patients
  • (Adjuvant therapy) Patients with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection
  • (In combination with ipilimumab) Patients with BRAF V600 wild-type unresectable or metastatic disease

Renal cell carcinoma

  • (In combination with ipilimumab) Patients with intermediate or poor-risk, previously untreated advanced disease

Urothelial carcinoma

  • Patients with locally advanced or metastatic disease that has progressed during or following platinum-based chemotherapy
  • Patients with disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy